Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to health and medical care, and does not recommend treatment plans (if mentioned), nor does it represent the platform's stance.Authorization is required for any article reprints.Recently, Leman Biotech’s independently developed metabolically enhanced BCMA CAR-T cell therapy achieved significant clinical progress. A patient with advanced multiple myeloma (MM) who had failed seven prior lines of therapy achieved complete tumor clearance and attained complete remission (CR) after receiving an ultra-low dose of the metabolically enhanced BCMA CAR-T treatment, marking the first case of complete remission in the company’s BCMA CAR-T pipeline.This treatment was led by the team of Professor Wang Xingbing from the Department of Hematology at the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital). The research project is titled “A Clinical Study on the Safety and Efficacy of Metabolism-Enhanced BCMA CAR-T Cell Injection for the Treatment of Relapsed or Refractory Plasmacytoma.” (Clinical Progress | Clinical Study on the Safety and Efficacy of Metabolism-Enhanced BCMA CAR-T Cell Injection for the Treatment of Relapsed/Refractory Plasmacytoma Officially Launched)The patient is a 62-year-old female who was diagnosed with multiple myeloma (IgG gamma type) in 2019, classified as Durie-Salmon (DS) stage IIIA, International Staging System (ISS) stage III, and Revised International Staging System (R-ISS) stage II, indicating high-risk advanced disease. In August 2025, she received an infusion of ultra-low dose metabolically enhanced BCMA CAR-T cells. The infusion process was safe, with no serious adverse events occurring during hospitalization.At month 9 (M9) post-infusion, the final efficacy assessment achieved complete response (CR). Furthermore, imaging results at month 6 (M6) post-infusion showed no evident lesions in the extramedullary sites that were present prior to treatment, further confirming the therapy’s ability to clear extramedullary disease.References:
Leman Biotech Official Website
Scan the QR code to join the groupMastering CAR-T Therapy, Stem Cell Therapy, and GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
